brand logo

Am Fam Physician. 2024;109(1):online

This clinical content conforms to AAFP criteria for CME.

Author disclosure: No relevant financial relationships.

Key Points for Practice

• For HIV PrEP, options include daily or episodic emtricitabine/tenofovir disoproxil fumarate (Truvada) or daily emtricitabine/tenofovir alafenamide (Descovy) and injectable cabotegravir (Apretude) every four to eight weeks.

• Rapid treatment initiation after HIV diagnosis improves outcomes; starting within seven days is recommended in patients without opportunistic infections and within 14 days in patients with most opportunistic infections.

• Most treatment failures are due to missed doses, so simplifying treatment regimens can be effective for patients with and without virologic suppression.

From the AFP Editors

Four decades after the initial HIV case was reported, strategies for treating and preventing the disease continue to advance. In the United States, the HIV epidemic continues to disproportionately affect people who are Black or Hispanic, men who have sex with men, people who are transgender, and individuals who use illicit drugs. HIV is increasingly diagnosed in older adults, and one-fourth of HIV-positive people will be older than 65 years by 2030.

HIV Prevention

Condom use remains the foundation of HIV prevention. Preexposure prophylaxis (PrEP) is proven to reduce incidence and should be discussed with all sexually active adults and adolescents, especially cisgender men and trans-gender individuals who have sex with men, people with a recent sexually transmitted infection, and those with substance use disorder or who inject nonprescription drugs. PrEP can be started immediately with negative point-of-care HIV testing or negative testing within seven days. Regular laboratory testing is recommended for patients taking PrEP (Table 1).

Already a member/subscriber?  Log In

Subscribe

From $165
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available
Subscribe

Issue Access

$59.95
  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

Coverage of guidelines from other organizations does not imply endorsement by AFP or the AAFP.

This series is coordinated by Michael J. Arnold, MD, Assistant Medical Editor.

A collection of Practice Guidelines published in AFP is available at https://www.aafp.org/afp/practguide.

Continue Reading

More in AFP

More in PubMed

Copyright © 2024 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.